Two YUTIQ injections versus sham for chronic eye inflammation
Part of Eyes & vision clinical trials.
This study tests whether receiving two YUTIQ injections works better than a sham (fake) treatment for long-lasting inflammation inside the back part of the eye. It is meant to reduce ongoing “posterior segment” inflammation and improve comfort and eye health when prior steroid treatments have helped but the inflammation keeps coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18+ (and you can understand and sign the consent forms).
- You can attend regular study visits and follow the treatment and testing plan for about 12 months.
- Your eye has long-term, non-infectious inflammation in the back of the eye (with or without some front eye inflammation).
- You’ve had inflammation that improved on at least one steroid treatment before, but then returned (chronicity).
- Your eye exam shows active inflammation with moderate vitreous haze (grade 2 or higher).
- You are not planning elective eye surgery during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
This trial looks at how often inflammatory flare-ups happen in patients with a type of eye inflammation called posterior uveitis. It focuses on people who have been treated with a fluocinolone acetonide implant, a tiny device placed in the eye that releases medicine over time, and aims to understand how well it controls inflammation.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This trial tests a new eye-numbing gel against the standard numbing method to see which works better for patients getting regular anti-VEGF injections in the eye.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.